edges:
  ACTIVITIES:
  - end: 133
    id: 131
    start: 21
  - end: 134
    id: 132
    start: 21
  ACTIVITY:
  - end: 133
    id: 364
    start: 80
  - end: 134
    id: 365
    start: 80
  - end: 134
    id: 371
    start: 84
  - end: 134
    id: 377
    start: 88
  - end: 134
    id: 383
    start: 92
  - end: 134
    id: 388
    start: 96
  ANALYSIS_POPULATION:
  - end: 103
    id: 100
    start: 102
  - end: 108
    id: 104
    start: 107
  BC_PROPERTIES:
  - end: 138
    id: 143
    start: 137
  - end: 150
    id: 150
    start: 149
  - end: 158
    id: 163
    start: 157
  - end: 161
    id: 164
    start: 157
  BC_PROPERTY_RESPONSE_CODES:
  - end: 139
    id: 138
    start: 138
  - end: 141
    id: 139
    start: 138
  - end: 143
    id: 140
    start: 138
  - end: 151
    id: 147
    start: 150
  - end: 162
    id: 158
    start: 161
  - end: 164
    id: 159
    start: 161
  - end: 166
    id: 160
    start: 161
  BC_SURROGATE:
  - end: 172
    id: 406
    start: 133
  BC_SURROGATES:
  - end: 172
    id: 170
    start: 21
  BIOMEDICAL_CONCEPT:
  - end: 137
    id: 403
    start: 133
  - end: 149
    id: 404
    start: 133
  - end: 157
    id: 405
    start: 133
  BIOMEDICAL_CONCEPTS:
  - end: 137
    id: 167
    start: 21
  - end: 149
    id: 168
    start: 21
  - end: 157
    id: 169
    start: 21
  BUSINESS_THERAPEUTIC_AREAS:
  - end: 5
    id: 4
    start: 1
  - end: 6
    id: 5
    start: 1
  CODE:
  - end: 140
    id: 135
    start: 139
  - end: 142
    id: 136
    start: 141
  - end: 144
    id: 137
    start: 143
  - end: 145
    id: 142
    start: 138
  - end: 147
    id: 145
    start: 137
  - end: 152
    id: 146
    start: 151
  - end: 153
    id: 149
    start: 150
  - end: 155
    id: 152
    start: 149
  - end: 159
    id: 154
    start: 158
  - end: 163
    id: 155
    start: 162
  - end: 165
    id: 156
    start: 164
  - end: 167
    id: 157
    start: 166
  - end: 168
    id: 162
    start: 161
  - end: 170
    id: 166
    start: 157
  CODES:
  - end: 35
    id: 32
    start: 34
  - end: 37
    id: 33
    start: 36
  - end: 39
    id: 36
    start: 38
  - end: 40
    id: 37
    start: 38
  - end: 42
    id: 38
    start: 41
  - end: 43
    id: 39
    start: 41
  CONTENTS:
  - end: 202
    id: 200
    start: 21
  - end: 203
    id: 201
    start: 21
  - end: 204
    id: 202
    start: 21
  - end: 205
    id: 203
    start: 21
  - end: 206
    id: 204
    start: 21
  - end: 207
    id: 205
    start: 21
  - end: 208
    id: 206
    start: 21
  - end: 209
    id: 207
    start: 21
  - end: 210
    id: 208
    start: 21
  - end: 211
    id: 209
    start: 21
  - end: 212
    id: 210
    start: 21
  - end: 213
    id: 211
    start: 21
  - end: 214
    id: 212
    start: 21
  - end: 215
    id: 213
    start: 21
  - end: 216
    id: 214
    start: 21
  - end: 217
    id: 215
    start: 21
  - end: 218
    id: 216
    start: 21
  - end: 219
    id: 217
    start: 21
  - end: 220
    id: 218
    start: 21
  - end: 221
    id: 219
    start: 21
  - end: 222
    id: 220
    start: 21
  - end: 223
    id: 221
    start: 21
  - end: 224
    id: 222
    start: 21
  - end: 225
    id: 223
    start: 21
  - end: 226
    id: 224
    start: 21
  - end: 227
    id: 225
    start: 21
  - end: 228
    id: 226
    start: 21
  - end: 229
    id: 227
    start: 21
  - end: 230
    id: 228
    start: 21
  - end: 231
    id: 229
    start: 21
  - end: 232
    id: 230
    start: 21
  - end: 233
    id: 231
    start: 21
  - end: 234
    id: 232
    start: 21
  - end: 235
    id: 233
    start: 21
  - end: 236
    id: 234
    start: 21
  - end: 237
    id: 235
    start: 21
  - end: 238
    id: 236
    start: 21
  - end: 239
    id: 237
    start: 21
  - end: 240
    id: 238
    start: 21
  - end: 241
    id: 239
    start: 21
  - end: 242
    id: 240
    start: 21
  - end: 243
    id: 241
    start: 21
  - end: 244
    id: 242
    start: 21
  - end: 245
    id: 243
    start: 21
  - end: 246
    id: 244
    start: 21
  - end: 247
    id: 245
    start: 21
  - end: 248
    id: 246
    start: 21
  - end: 249
    id: 247
    start: 21
  - end: 250
    id: 248
    start: 21
  - end: 251
    id: 249
    start: 21
  - end: 252
    id: 250
    start: 21
  - end: 253
    id: 251
    start: 21
  - end: 254
    id: 252
    start: 21
  - end: 255
    id: 253
    start: 21
  - end: 256
    id: 254
    start: 21
  - end: 257
    id: 255
    start: 21
  - end: 258
    id: 256
    start: 21
  - end: 259
    id: 257
    start: 21
  - end: 260
    id: 258
    start: 21
  - end: 261
    id: 259
    start: 21
  - end: 262
    id: 260
    start: 21
  - end: 263
    id: 261
    start: 21
  - end: 264
    id: 262
    start: 21
  - end: 265
    id: 263
    start: 21
  - end: 266
    id: 264
    start: 21
  - end: 267
    id: 265
    start: 21
  - end: 268
    id: 266
    start: 21
  - end: 269
    id: 267
    start: 21
  - end: 270
    id: 268
    start: 21
  - end: 271
    id: 269
    start: 21
  - end: 272
    id: 270
    start: 21
  - end: 273
    id: 271
    start: 21
  - end: 274
    id: 272
    start: 21
  - end: 275
    id: 273
    start: 21
  - end: 276
    id: 274
    start: 21
  - end: 277
    id: 275
    start: 21
  - end: 278
    id: 276
    start: 21
  - end: 279
    id: 277
    start: 21
  - end: 280
    id: 278
    start: 21
  - end: 281
    id: 279
    start: 21
  - end: 282
    id: 280
    start: 21
  - end: 283
    id: 281
    start: 21
  - end: 284
    id: 282
    start: 21
  - end: 285
    id: 283
    start: 21
  - end: 286
    id: 284
    start: 21
  - end: 287
    id: 285
    start: 21
  - end: 288
    id: 286
    start: 21
  - end: 289
    id: 287
    start: 21
  - end: 290
    id: 288
    start: 21
  - end: 291
    id: 289
    start: 21
  - end: 292
    id: 290
    start: 21
  - end: 293
    id: 291
    start: 21
  - end: 294
    id: 292
    start: 21
  - end: 295
    id: 293
    start: 21
  - end: 296
    id: 294
    start: 21
  - end: 297
    id: 295
    start: 21
  - end: 298
    id: 296
    start: 21
  - end: 299
    id: 297
    start: 21
  - end: 300
    id: 298
    start: 21
  - end: 301
    id: 299
    start: 21
  - end: 302
    id: 300
    start: 21
  - end: 303
    id: 301
    start: 21
  - end: 304
    id: 302
    start: 21
  - end: 305
    id: 303
    start: 21
  - end: 306
    id: 304
    start: 21
  - end: 307
    id: 305
    start: 21
  - end: 308
    id: 306
    start: 21
  - end: 309
    id: 307
    start: 21
  - end: 310
    id: 308
    start: 21
  - end: 311
    id: 309
    start: 21
  - end: 312
    id: 310
    start: 21
  - end: 313
    id: 311
    start: 21
  - end: 314
    id: 312
    start: 21
  - end: 315
    id: 313
    start: 21
  - end: 316
    id: 314
    start: 21
  - end: 317
    id: 315
    start: 21
  - end: 318
    id: 316
    start: 21
  - end: 319
    id: 317
    start: 21
  - end: 320
    id: 318
    start: 21
  - end: 321
    id: 319
    start: 21
  - end: 322
    id: 320
    start: 21
  - end: 323
    id: 321
    start: 21
  - end: 324
    id: 322
    start: 21
  - end: 325
    id: 323
    start: 21
  - end: 326
    id: 324
    start: 21
  - end: 327
    id: 325
    start: 21
  - end: 328
    id: 326
    start: 21
  - end: 329
    id: 327
    start: 21
  - end: 330
    id: 328
    start: 21
  - end: 331
    id: 329
    start: 21
  - end: 332
    id: 330
    start: 21
  - end: 333
    id: 331
    start: 21
  CONTENT_CHILD:
  - end: 203
    id: 414
    start: 202
  - end: 207
    id: 415
    start: 202
  - end: 210
    id: 416
    start: 202
  - end: 212
    id: 417
    start: 202
  - end: 221
    id: 418
    start: 202
  - end: 232
    id: 419
    start: 202
  - end: 252
    id: 420
    start: 202
  - end: 260
    id: 421
    start: 202
  - end: 294
    id: 422
    start: 202
  - end: 309
    id: 423
    start: 202
  - end: 315
    id: 424
    start: 202
  - end: 319
    id: 425
    start: 202
  - end: 324
    id: 426
    start: 202
  - end: 332
    id: 427
    start: 202
  - end: 333
    id: 428
    start: 202
  - end: 204
    id: 429
    start: 203
  - end: 205
    id: 430
    start: 203
  - end: 206
    id: 431
    start: 203
  - end: 208
    id: 432
    start: 207
  - end: 209
    id: 433
    start: 207
  - end: 211
    id: 434
    start: 210
  - end: 213
    id: 435
    start: 212
  - end: 215
    id: 436
    start: 212
  - end: 219
    id: 437
    start: 212
  - end: 220
    id: 438
    start: 212
  - end: 214
    id: 439
    start: 213
  - end: 216
    id: 440
    start: 215
  - end: 217
    id: 441
    start: 215
  - end: 218
    id: 442
    start: 215
  - end: 222
    id: 443
    start: 221
  - end: 223
    id: 444
    start: 221
  - end: 224
    id: 445
    start: 221
  - end: 225
    id: 446
    start: 221
  - end: 226
    id: 447
    start: 221
  - end: 231
    id: 448
    start: 221
  - end: 227
    id: 449
    start: 226
  - end: 228
    id: 450
    start: 226
  - end: 229
    id: 451
    start: 226
  - end: 230
    id: 452
    start: 226
  - end: 233
    id: 453
    start: 232
  - end: 234
    id: 454
    start: 232
  - end: 235
    id: 455
    start: 232
  - end: 237
    id: 456
    start: 232
  - end: 238
    id: 457
    start: 232
  - end: 242
    id: 458
    start: 232
  - end: 246
    id: 459
    start: 232
  - end: 247
    id: 460
    start: 232
  - end: 236
    id: 461
    start: 235
  - end: 239
    id: 462
    start: 238
  - end: 240
    id: 463
    start: 238
  - end: 241
    id: 464
    start: 238
  - end: 243
    id: 465
    start: 242
  - end: 244
    id: 466
    start: 242
  - end: 245
    id: 467
    start: 242
  - end: 248
    id: 468
    start: 247
  - end: 249
    id: 469
    start: 247
  - end: 250
    id: 470
    start: 247
  - end: 251
    id: 471
    start: 247
  - end: 253
    id: 472
    start: 252
  - end: 257
    id: 473
    start: 252
  - end: 258
    id: 474
    start: 252
  - end: 259
    id: 475
    start: 252
  - end: 254
    id: 476
    start: 253
  - end: 255
    id: 477
    start: 253
  - end: 256
    id: 478
    start: 253
  - end: 261
    id: 479
    start: 260
  - end: 262
    id: 480
    start: 260
  - end: 263
    id: 481
    start: 260
  - end: 269
    id: 482
    start: 260
  - end: 280
    id: 483
    start: 260
  - end: 283
    id: 484
    start: 260
  - end: 289
    id: 485
    start: 260
  - end: 290
    id: 486
    start: 260
  - end: 291
    id: 487
    start: 260
  - end: 292
    id: 488
    start: 260
  - end: 264
    id: 489
    start: 263
  - end: 265
    id: 490
    start: 263
  - end: 266
    id: 491
    start: 263
  - end: 267
    id: 492
    start: 263
  - end: 268
    id: 493
    start: 263
  - end: 270
    id: 494
    start: 269
  - end: 271
    id: 495
    start: 269
  - end: 272
    id: 496
    start: 269
  - end: 273
    id: 497
    start: 269
  - end: 274
    id: 498
    start: 269
  - end: 275
    id: 499
    start: 269
  - end: 276
    id: 500
    start: 269
  - end: 277
    id: 501
    start: 269
  - end: 278
    id: 502
    start: 269
  - end: 279
    id: 503
    start: 269
  - end: 281
    id: 504
    start: 280
  - end: 282
    id: 505
    start: 280
  - end: 284
    id: 506
    start: 283
  - end: 285
    id: 507
    start: 283
  - end: 286
    id: 508
    start: 283
  - end: 287
    id: 509
    start: 283
  - end: 288
    id: 510
    start: 283
  - end: 293
    id: 511
    start: 292
  - end: 295
    id: 512
    start: 294
  - end: 296
    id: 513
    start: 294
  - end: 302
    id: 514
    start: 294
  - end: 303
    id: 515
    start: 294
  - end: 304
    id: 516
    start: 294
  - end: 305
    id: 517
    start: 294
  - end: 306
    id: 518
    start: 294
  - end: 307
    id: 519
    start: 294
  - end: 308
    id: 520
    start: 294
  - end: 297
    id: 521
    start: 296
  - end: 298
    id: 522
    start: 296
  - end: 299
    id: 523
    start: 296
  - end: 300
    id: 524
    start: 296
  - end: 301
    id: 525
    start: 296
  - end: 310
    id: 526
    start: 309
  - end: 311
    id: 527
    start: 309
  - end: 312
    id: 528
    start: 309
  - end: 313
    id: 529
    start: 309
  - end: 314
    id: 530
    start: 309
  - end: 316
    id: 531
    start: 315
  - end: 317
    id: 532
    start: 315
  - end: 318
    id: 533
    start: 315
  - end: 320
    id: 534
    start: 319
  - end: 321
    id: 535
    start: 319
  - end: 322
    id: 536
    start: 319
  - end: 323
    id: 537
    start: 319
  - end: 325
    id: 538
    start: 324
  - end: 329
    id: 539
    start: 324
  - end: 330
    id: 540
    start: 324
  - end: 331
    id: 541
    start: 324
  - end: 326
    id: 542
    start: 325
  - end: 327
    id: 543
    start: 325
  - end: 328
    id: 544
    start: 325
  COUNTRY:
  - end: 11
    id: 7
    start: 10
  - end: 16
    id: 11
    start: 15
  DATA_ORIGIN_TYPE:
  - end: 175
    id: 172
    start: 173
  - end: 178
    id: 174
    start: 176
  DEFAULT_CONDITION:
  - end: 84
    id: 362
    start: 80
  - end: 88
    id: 369
    start: 84
  - end: 92
    id: 375
    start: 88
  - end: 96
    id: 381
    start: 92
  ENCOUNTERS:
  - end: 110
    id: 126
    start: 21
  - end: 116
    id: 127
    start: 21
  - end: 120
    id: 128
    start: 21
  - end: 125
    id: 129
    start: 21
  - end: 129
    id: 130
    start: 21
  ENCOUNTER_CONTACT_MODES:
  - end: 113
    id: 110
    start: 110
  - end: 119
    id: 115
    start: 116
  - end: 123
    id: 118
    start: 120
  - end: 128
    id: 122
    start: 125
  - end: 132
    id: 125
    start: 129
  ENCOUNTER_ENVIRONMENTAL_SETTING:
  - end: 112
    id: 109
    start: 110
  - end: 118
    id: 114
    start: 116
  - end: 122
    id: 117
    start: 120
  - end: 127
    id: 121
    start: 125
  - end: 131
    id: 124
    start: 129
  ENDPOINT_LEVEL:
  - end: 53
    id: 49
    start: 52
  - end: 57
    id: 52
    start: 56
  - end: 59
    id: 53
    start: 58
  - end: 61
    id: 54
    start: 60
  - end: 63
    id: 55
    start: 62
  - end: 65
    id: 56
    start: 64
  - end: 67
    id: 57
    start: 66
  - end: 69
    id: 58
    start: 68
  - end: 71
    id: 59
    start: 70
  - end: 73
    id: 60
    start: 72
  - end: 75
    id: 61
    start: 74
  - end: 77
    id: 62
    start: 76
  EPOCH:
  - end: 179
    id: 363
    start: 80
  - end: 181
    id: 370
    start: 84
  - end: 183
    id: 376
    start: 88
  - end: 183
    id: 382
    start: 92
  - end: 185
    id: 387
    start: 96
  INTERCURRENT_EVENTS:
  - end: 104
    id: 101
    start: 102
  - end: 105
    id: 102
    start: 102
  - end: 106
    id: 103
    start: 102
  - end: 109
    id: 105
    start: 107
  INTERVENTION_MODEL:
  - end: 25
    id: 23
    start: 21
  NEXT_ACTIVITY:
  - end: 134
    id: 402
    start: 133
  NEXT_ENCOUNTER:
  - end: 116
    id: 394
    start: 110
  - end: 120
    id: 396
    start: 116
  - end: 125
    id: 398
    start: 120
  - end: 129
    id: 400
    start: 125
  NEXT_STUDY_EPOCH:
  - end: 181
    id: 408
    start: 179
  - end: 183
    id: 410
    start: 181
  - end: 185
    id: 412
    start: 183
  OBJECTIVE_ENDPOINTS:
  - end: 52
    id: 50
    start: 50
  - end: 56
    id: 63
    start: 54
  - end: 58
    id: 64
    start: 54
  - end: 60
    id: 65
    start: 54
  - end: 62
    id: 66
    start: 54
  - end: 64
    id: 67
    start: 54
  - end: 66
    id: 68
    start: 54
  - end: 68
    id: 69
    start: 54
  - end: 70
    id: 70
    start: 54
  - end: 72
    id: 71
    start: 54
  - end: 74
    id: 72
    start: 54
  - end: 76
    id: 73
    start: 54
  OBJECTIVE_LEVEL:
  - end: 51
    id: 48
    start: 50
  - end: 55
    id: 51
    start: 54
  ORGANIZATION_LEGAL_ADDRESS:
  - end: 10
    id: 8
    start: 8
  - end: 15
    id: 12
    start: 13
  PLANNED_SEX_OF_PARTICIPANTS:
  - end: 45
    id: 42
    start: 44
  - end: 47
    id: 43
    start: 46
  - end: 49
    id: 44
    start: 48
  PREVIOUS_ACTIVITY:
  - end: 133
    id: 407
    start: 134
  PREVIOUS_ENCOUNTER:
  - end: 110
    id: 395
    start: 116
  - end: 116
    id: 397
    start: 120
  - end: 120
    id: 399
    start: 125
  - end: 125
    id: 401
    start: 129
  PREVIOUS_STUDY_EPOCH:
  - end: 179
    id: 409
    start: 181
  - end: 181
    id: 411
    start: 183
  - end: 183
    id: 413
    start: 185
  PROTOCOL_STATUS:
  - end: 18
    id: 16
    start: 17
  - end: 20
    id: 17
    start: 19
  RELATIVE_FROM_SCHEDULED_INSTANCE:
  - end: 80
    id: 360
    start: 81
  - end: 84
    id: 367
    start: 85
  - end: 88
    id: 373
    start: 89
  - end: 92
    id: 379
    start: 93
  - end: 96
    id: 385
    start: 97
  RELATIVE_TO_SCHEDULED_INSTANCE:
  - end: 84
    id: 361
    start: 81
  - end: 88
    id: 368
    start: 85
  - end: 88
    id: 374
    start: 89
  - end: 88
    id: 380
    start: 93
  - end: 92
    id: 386
    start: 97
  SCHEDULED_ACTIVITY_INSTANCE_ENCOUNTER:
  - end: 110
    id: 366
    start: 80
  - end: 116
    id: 372
    start: 84
  - end: 120
    id: 378
    start: 88
  - end: 125
    id: 384
    start: 92
  - end: 129
    id: 389
    start: 96
  SCHEDULED_INSTANCE_TIMINGS:
  - end: 81
    id: 79
    start: 80
  - end: 85
    id: 82
    start: 84
  - end: 89
    id: 85
    start: 88
  - end: 93
    id: 88
    start: 92
  - end: 97
    id: 91
    start: 96
  SCHEDULE_TIMELINE_ENTRY:
  - end: 80
    id: 359
    start: 78
  SCHEDULE_TIMELINE_EXITS:
  - end: 79
    id: 76
    start: 78
  SCHEDULE_TIMELINE_INSTANCES:
  - end: 80
    id: 92
    start: 78
  - end: 84
    id: 93
    start: 78
  - end: 88
    id: 94
    start: 78
  - end: 92
    id: 95
    start: 78
  - end: 96
    id: 96
    start: 78
  STANDARD_CODE:
  - end: 4
    id: 2
    start: 3
  - end: 136
    id: 133
    start: 135
  - end: 146
    id: 141
    start: 145
  - end: 148
    id: 144
    start: 147
  - end: 154
    id: 148
    start: 153
  - end: 156
    id: 151
    start: 155
  - end: 160
    id: 153
    start: 159
  - end: 169
    id: 161
    start: 168
  - end: 171
    id: 165
    start: 170
  STUDY_ARM:
  - end: 173
    id: 333
    start: 26
  - end: 173
    id: 336
    start: 27
  - end: 173
    id: 339
    start: 28
  - end: 173
    id: 343
    start: 29
  - end: 176
    id: 346
    start: 30
  - end: 176
    id: 349
    start: 31
  - end: 176
    id: 352
    start: 32
  - end: 176
    id: 356
    start: 33
  STUDY_ARMS:
  - end: 173
    id: 175
    start: 21
  - end: 176
    id: 176
    start: 21
  STUDY_CELLS:
  - end: 26
    id: 24
    start: 21
  - end: 27
    id: 25
    start: 21
  - end: 28
    id: 26
    start: 21
  - end: 29
    id: 27
    start: 21
  - end: 30
    id: 28
    start: 21
  - end: 31
    id: 29
    start: 21
  - end: 32
    id: 30
    start: 21
  - end: 33
    id: 31
    start: 21
  STUDY_DESIGNS:
  - end: 21
    id: 332
    start: 1
  STUDY_DESIGN_BLINDING_SCHEME:
  - end: 135
    id: 134
    start: 21
  STUDY_ELEMENT:
  - end: 187
    id: 335
    start: 26
  - end: 190
    id: 338
    start: 27
  - end: 193
    id: 341
    start: 28
  - end: 196
    id: 342
    start: 28
  - end: 199
    id: 345
    start: 29
  - end: 187
    id: 348
    start: 30
  - end: 190
    id: 351
    start: 31
  - end: 196
    id: 354
    start: 32
  - end: 193
    id: 355
    start: 32
  - end: 199
    id: 358
    start: 33
  STUDY_ELEMENTS:
  - end: 187
    id: 195
    start: 21
  - end: 190
    id: 196
    start: 21
  - end: 193
    id: 197
    start: 21
  - end: 196
    id: 198
    start: 21
  - end: 199
    id: 199
    start: 21
  STUDY_EPOCH:
  - end: 179
    id: 334
    start: 26
  - end: 181
    id: 337
    start: 27
  - end: 183
    id: 340
    start: 28
  - end: 185
    id: 344
    start: 29
  - end: 179
    id: 347
    start: 30
  - end: 181
    id: 350
    start: 31
  - end: 183
    id: 353
    start: 32
  - end: 185
    id: 357
    start: 33
  STUDY_EPOCHS:
  - end: 179
    id: 181
    start: 21
  - end: 181
    id: 182
    start: 21
  - end: 183
    id: 183
    start: 21
  - end: 185
    id: 184
    start: 21
  STUDY_ESTIMANDS:
  - end: 102
    id: 106
    start: 21
  - end: 107
    id: 107
    start: 21
  STUDY_IDENTIFIERS:
  - end: 7
    id: 14
    start: 1
  - end: 12
    id: 15
    start: 1
  STUDY_IDENTIFIER_SCOPE:
  - end: 8
    id: 9
    start: 7
  - end: 13
    id: 13
    start: 12
  STUDY_INDICATIONS:
  - end: 34
    id: 34
    start: 21
  - end: 36
    id: 35
    start: 21
  STUDY_INVESTIGATIONAL_INTERVENTIONS:
  - end: 38
    id: 40
    start: 21
  - end: 41
    id: 41
    start: 21
  STUDY_OBJECTIVES:
  - end: 50
    id: 74
    start: 21
  - end: 54
    id: 75
    start: 21
  STUDY_PHASE:
  - end: 3
    id: 3
    start: 1
  STUDY_POPULATIONS:
  - end: 44
    id: 45
    start: 21
  - end: 46
    id: 46
    start: 21
  - end: 48
    id: 47
    start: 21
  STUDY_PROTOCOL_VERSIONS:
  - end: 17
    id: 18
    start: 1
  - end: 19
    id: 19
    start: 1
  STUDY_SCHEDULE_TIMELINES:
  - end: 78
    id: 97
    start: 21
  THERAPEUTIC_AREAS:
  - end: 100
    id: 98
    start: 21
  - end: 101
    id: 99
    start: 21
  TIMING_RELATIVE_TO_FROM:
  - end: 83
    id: 78
    start: 81
  - end: 87
    id: 81
    start: 85
  - end: 91
    id: 84
    start: 89
  - end: 95
    id: 87
    start: 93
  - end: 99
    id: 90
    start: 97
  TRANSITION_END_RULE:
  - end: 115
    id: 112
    start: 110
  - end: 189
    id: 186
    start: 187
  - end: 192
    id: 188
    start: 190
  - end: 195
    id: 190
    start: 193
  - end: 198
    id: 192
    start: 196
  - end: 201
    id: 194
    start: 199
  TRANSITION_START_RULE:
  - end: 114
    id: 111
    start: 110
  - end: 124
    id: 119
    start: 120
  - end: 188
    id: 185
    start: 187
  - end: 191
    id: 187
    start: 190
  - end: 194
    id: 189
    start: 193
  - end: 197
    id: 191
    start: 196
  - end: 200
    id: 193
    start: 199
  TREATMENT:
  - end: 38
    id: 390
    start: 102
  - end: 41
    id: 392
    start: 107
  TRIAL_INTENT_TYPES:
  - end: 22
    id: 20
    start: 21
  - end: 23
    id: 21
    start: 21
  TRIAL_TYPES:
  - end: 24
    id: 22
    start: 21
  TYPE:
  - end: 2
    id: 1
    start: 1
  - end: 9
    id: 6
    start: 8
  - end: 14
    id: 10
    start: 13
  - end: 82
    id: 77
    start: 81
  - end: 86
    id: 80
    start: 85
  - end: 90
    id: 83
    start: 89
  - end: 94
    id: 86
    start: 93
  - end: 98
    id: 89
    start: 97
  - end: 111
    id: 108
    start: 110
  - end: 117
    id: 113
    start: 116
  - end: 121
    id: 116
    start: 120
  - end: 126
    id: 120
    start: 125
  - end: 130
    id: 123
    start: 129
  - end: 174
    id: 171
    start: 173
  - end: 177
    id: 173
    start: 176
  - end: 180
    id: 177
    start: 179
  - end: 182
    id: 178
    start: 181
  - end: 184
    id: 179
    start: 183
  - end: 186
    id: 180
    start: 185
  VARIABLE_OF_INTEREST:
  - end: 52
    id: 391
    start: 102
  - end: 56
    id: 393
    start: 107
nodes:
  Activity:
  - activityIsConditional: false
    activityIsConditionalReason: ''
    definedProcedures: []
    description: Basic Demog
    id: Activity_1
    label: ''
    name: Demographics
  - activityIsConditional: true
    activityIsConditionalReason: Only do this if they have two heads
    definedProcedures: []
    description: Something weird
    id: Activity_2
    label: ''
    name: Something Else
  Address:
  - city: city
    district: district
    id: Address_1
    line: line
    postalCode: postal_code
    state: state
    text: line, city, district, state, postal_code, United Kingdom of Great Britain
      and Northern Ireland
  - city: In a City
    district: In a District
    id: Address_2
    line: Somewhere
    postalCode: '12345'
    state: In a big state
    text: Somewhere, In a City, In a District, In a big state, 12345, France
  AliasCode:
  - id: AliasCode_1
    standardCodeAliases: []
  - id: AliasCode_2
    standardCodeAliases: []
  - id: AliasCode_4
    standardCodeAliases: []
  - id: AliasCode_3
    standardCodeAliases: []
  - id: AliasCode_6
    standardCodeAliases: []
  - id: AliasCode_5
    standardCodeAliases: []
  - id: AliasCode_8
    standardCodeAliases: []
  - id: AliasCode_9
    standardCodeAliases: []
  - id: AliasCode_7
    standardCodeAliases: []
  AnalysisPopulation:
  - description: ITT
    id: AnalysisPopulation_1
  - description: ITT
    id: AnalysisPopulation_2
  BiomedicalConcept:
  - bcReference: /mdr/bc/packages/2023-03-31/biomedicalconcepts/C28421
    bcSynonyms: []
    id: BiomedicalConcept_1
    label: Sex
    name: Sex
  - bcReference: /mdr/bc/packages/2023-03-31/biomedicalconcepts/C17049
    bcSynonyms:
    - Racial Group
    id: BiomedicalConcept_2
    label: Race
    name: Race
  - bcReference: /mdr/bc/packages/2022-10-26/biomedicalconcepts/C81328
    bcSynonyms:
    - Weight
    id: BiomedicalConcept_3
    label: Body Weight
    name: Body Weight
  BiomedicalConceptProperty:
  - bcPropertyDatatype: string
    bcPropertyEnabled: true
    bcPropertyRequired: true
    id: BiomedicalConceptProperty_1
    label: Sex
    name: Sex
  - bcPropertyDatatype: string
    bcPropertyEnabled: true
    bcPropertyRequired: true
    id: BiomedicalConceptProperty_2
    label: Race
    name: Race
  - bcPropertyDatatype: decimal
    bcPropertyEnabled: true
    bcPropertyRequired: true
    bcPropertyResponseCodes: []
    id: BiomedicalConceptProperty_3
    label: Vital Signs Result
    name: Vital Signs Result
  - bcPropertyDatatype: string
    bcPropertyEnabled: true
    bcPropertyRequired: true
    id: BiomedicalConceptProperty_4
    label: Unit of Weight
    name: Unit of Weight
  BiomedicalConceptSurrogate:
  - bcSurrogateReference: None set
    description: Age
    id: BiomedicalConceptSurrogate_1
    label: Age
    name: Age
  Code:
  - code: C98388
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Interventional Study
    id: Code_1
  - code: C15602
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Phase III Trial
    id: Code_2
  - code: VAC
    codeSystem: SPONSOR
    codeSystemVersion: '12'
    decode: Vacines Group
    id: Code_3
  - code: REG
    codeSystem: SPONSOR
    codeSystemVersion: '12'
    decode: Regulatory
    id: Code_4
  - code: C93453
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Study Registry
    id: Code_7
  - code: GBR
    codeSystem: ISO 3166 1 alpha3
    codeSystemVersion: 2020-08
    decode: United Kingdom of Great Britain and Northern Ireland
    id: Code_8
  - code: C70793
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Clinical Study Sponsor
    id: Code_9
  - code: FRA
    codeSystem: ISO 3166 1 alpha3
    codeSystemVersion: 2020-08
    decode: France
    id: Code_10
  - code: C85255
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Draft
    id: Code_5
  - code: C85255
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Draft
    id: Code_6
  - code: C15714
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Basic Research
    id: Code_39
  - code: C139174
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Device Feasibility Study
    id: Code_40
  - code: C49666
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Efficacy Study
    id: Code_41
  - code: C82639
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Parallel Study
    id: Code_42
  - code: '12345'
    codeSystem: SNOMED
    codeSystemVersion: January 31, 2018
    decode: Indication1
    id: Code_82
  - code: '345678'
    codeSystem: SNOMED
    codeSystemVersion: January 31, 2018
    decode: Indication2
    id: Code_85
  - code: X
    codeSystem: ICD-10
    codeSystemVersion: None set
    decode: Y
    id: Code_83
  - code: A
    codeSystem: SNOMED
    codeSystemVersion: January 31, 2018
    decode: B
    id: Code_84
  - code: DD
    codeSystem: ICD-10
    codeSystemVersion: None set
    decode: CC
    id: Code_86
  - code: A
    codeSystem: SNOMED
    codeSystemVersion: January 31, 2018
    decode: B
    id: Code_87
  - code: C49636
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Both
    id: Code_88
  - code: C20197
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Male
    id: Code_89
  - code: C16576
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Female
    id: Code_90
  - code: C85826
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Trial Primary Objective
    id: Code_92
  - code: C94496
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Primary Endpoint
    id: Code_91
  - code: C85827
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Trial Secondary Objective
    id: Code_94
  - code: C139173
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Secondary Endpoint
    id: Code_93
  - code: C139173
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Secondary Endpoint
    id: Code_95
  - code: C139173
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Secondary Endpoint
    id: Code_96
  - code: C139173
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Secondary Endpoint
    id: Code_97
  - code: C139173
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Secondary Endpoint
    id: Code_98
  - code: C139173
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Secondary Endpoint
    id: Code_99
  - code: C139173
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Secondary Endpoint
    id: Code_100
  - code: C139173
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Secondary Endpoint
    id: Code_101
  - code: C139173
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Secondary Endpoint
    id: Code_102
  - code: C139173
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Secondary Endpoint
    id: Code_103
  - code: C139173
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Secondary Endpoint
    id: Code_104
  - code: C99901x2
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Before
    id: Code_45
  - code: C99900x1
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Start to Start
    id: Code_47
  - code: C99901x2
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Before
    id: Code_50
  - code: C99900x1
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Start to Start
    id: Code_52
  - code: C99901x3
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Fixed Reference
    id: Code_53
  - code: C99900x1
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Start to Start
    id: Code_57
  - code: C99901x1
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: After
    id: Code_59
  - code: C99900x1
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Start to Start
    id: Code_62
  - code: C99901x1
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: After
    id: Code_64
  - code: C99900x1
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Start to Start
    id: Code_67
  - code: T2_DIABETES
    codeSystem: SPONSOR
    codeSystemVersion: '12'
    decode: Type 2 diabetes
    id: Code_36
  - code: '73211009'
    codeSystem: SNOMED
    codeSystemVersion: January 31, 2018
    decode: Diabetes mellitus (disorder)
    id: Code_37
  - code: C25716
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Visit
    id: Code_13
  - code: C51282
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Clinic
    id: Code_14
  - code: C175574
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: In Person
    id: Code_15
  - code: C25716
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Visit
    id: Code_16
  - code: C51282
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Clinic
    id: Code_17
  - code: C175574
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: In Person
    id: Code_18
  - code: C25716
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Visit
    id: Code_19
  - code: C51282
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Clinic
    id: Code_20
  - code: C175574
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: In Person
    id: Code_21
  - code: C25716
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Visit
    id: Code_22
  - code: C51282
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Clinic
    id: Code_23
  - code: C175574
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: In Person
    id: Code_24
  - code: C25716
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Visit
    id: Code_25
  - code: C18002
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Home
    id: Code_26
  - code: C171537
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Telephone Call
    id: Code_27
  - code: C49659
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Open Label Study
    id: Code_38
  - code: C20197
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Male
    id: Code_69
  - code: C16576
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Female
    id: Code_70
  - code: C17998
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Unknown
    id: Code_71
  - code: C28421
    codeSystem: NCI Thesaurus
    codeSystemVersion: ''
    decode: Sex
    id: Code_72
  - code: C28421
    codeSystem: NCI Thesaurus
    codeSystemVersion: ''
    decode: Sex
    id: Code_68
  - code: C17998
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Unknown
    id: Code_74
  - code: C17049
    codeSystem: NCI Thesaurus
    codeSystemVersion: ''
    decode: Race
    id: Code_75
  - code: C17049
    codeSystem: NCI Thesaurus
    codeSystemVersion: ''
    decode: Race
    id: Code_73
  - code: C173522
    codeSystem: NCI Thesaurus
    codeSystemVersion: ''
    decode: Vital Signs Result
    id: Code_77
  - code: C28252
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Kilogram
    id: Code_78
  - code: C48155
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Gram
    id: Code_79
  - code: C48531
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Pound
    id: Code_80
  - code: C48208
    codeSystem: NCI Thesaurus
    codeSystemVersion: ''
    decode: Unit of Weight
    id: Code_81
  - code: C81328
    codeSystem: NCI Thesaurus
    codeSystemVersion: ''
    decode: Body Weight
    id: Code_76
  - code: C174267
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Active Comparator Arm
    id: Code_28
  - code: C188866
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Data Generated Within Study
    id: Code_29
  - code: C174268
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Placebo Comparator Arm
    id: Code_30
  - code: C188866
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Data Generated Within Study
    id: Code_31
  - code: C48262
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Trial Screening
    id: Code_32
  - code: C125938
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Baseline Epoch
    id: Code_33
  - code: C101526
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Treatment Epoch
    id: Code_34
  - code: C99158
    codeSystem: http://www.cdisc.org
    codeSystemVersion: '2022-12-16'
    decode: Clinical Study Follow-up
    id: Code_35
  Content:
  - id: Content_1
    name: ROOT
    sectionNumber: '0'
    sectionTitle: Root
    text: ''
  - id: Content_2
    name: SECTION 1
    sectionNumber: '1'
    sectionTitle: PROTOCOL SUMMARY
    text: <usdm:ref klass="StudyIdentifier" id="StudyIdentifier_1" attribute="studyIdentifier"/>
  - id: Content_3
    name: SECTION 1.1
    sectionNumber: '1.1'
    sectionTitle: Protocol Synopsis
    text: ''
  - id: Content_4
    name: SECTION 1.2
    sectionNumber: '1.2'
    sectionTitle: Trial Schema
    text: ''
  - id: Content_5
    name: SECTION 1.3
    sectionNumber: '1.3'
    sectionTitle: Schedule of Activities
    text: ''
  - id: Content_6
    name: SECTION 2
    sectionNumber: '2'
    sectionTitle: INTRODUCTION
    text: ''
  - id: Content_7
    name: SECTION 2.1
    sectionNumber: '2.1'
    sectionTitle: Purpose of Trial
    text: ''
  - id: Content_8
    name: SECTION 2.2
    sectionNumber: '2.2'
    sectionTitle: Summary of Benefits and Risks
    text: ''
  - id: Content_9
    name: SECTION 3
    sectionNumber: '3'
    sectionTitle: TRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS
    text: ''
  - id: Content_10
    name: SECTION 3.1
    sectionNumber: '3.1'
    sectionTitle: Primary Objectives
    text: "<table>\n  <tr>\n    <th style=\"vertical-align: top\">Primary Objective</th>\n\
      \    <th style=\"vertical-align: top\">Primary Endpoint</th>\n  </tr>\n  <tr>\n\
      \    <td style=\"vertical-align: top\"><usdm:ref klass=\"Objective\" namexref=\"\
      OBJ1\" attribute=\"description\"/></td>\n    <td style=\"vertical-align: top\"\
      ><usdm:ref klass=\"Endpoint\" id=\"Endpoint_1\" attribute=\"description\"/></td>\n\
      \  </tr>\n</table>"
  - id: Content_11
    name: SECTION 4
    sectionNumber: '4'
    sectionTitle: TRIAL DESIGN
    text: ''
  - id: Content_12
    name: SECTION 4.1
    sectionNumber: '4.1'
    sectionTitle: Description of Trial Design
    text: ''
  - id: Content_13
    name: SECTION 4.1.1
    sectionNumber: 4.1.1
    sectionTitle: Participant Input into Design
    text: ''
  - id: Content_14
    name: SECTION 4.2
    sectionNumber: '4.2'
    sectionTitle: Rationale for Trial Design
    text: ''
  - id: Content_15
    name: SECTION 4.2.1
    sectionNumber: 4.2.1
    sectionTitle: Rationale for Comparator
    text: ''
  - id: Content_16
    name: SECTION 4.2.2
    sectionNumber: 4.2.2
    sectionTitle: Rationale for Adaptive or Novel Trial Design
    text: ''
  - id: Content_17
    name: SECTION 4.2.3
    sectionNumber: 4.2.3
    sectionTitle: Other Trial Design Considerations
    text: ''
  - id: Content_18
    name: SECTION 4.3
    sectionNumber: '4.3'
    sectionTitle: Access to Trial Intervention After End of Trial
    text: ''
  - id: Content_19
    name: SECTION 4.4
    sectionNumber: '4.4'
    sectionTitle: Start of Trial and End of Trial
    text: ''
  - id: Content_20
    name: SECTION 5
    sectionNumber: '5'
    sectionTitle: TRIAL POPULATION
    text: ''
  - id: Content_21
    name: SECTION 5.1
    sectionNumber: '5.1'
    sectionTitle: Selection of Trial Population
    text: ''
  - id: Content_22
    name: SECTION 5.2
    sectionNumber: '5.2'
    sectionTitle: Rationale for Trial Population
    text: ''
  - id: Content_23
    name: SECTION 5.3
    sectionNumber: '5.3'
    sectionTitle: Inclusion Criteria
    text: "<p>Inclusion criteria are:</p>\n<ul>\n  <li>1. Something</li>\n  <li>2.\
      \ Something else</li>\n</ul>"
  - id: Content_24
    name: SECTION 5.4
    sectionNumber: '5.4'
    sectionTitle: Exclusion Criteria
    text: "<p>Exclusion criteria are:</p>\n<ul>\n  <li>1. Dont do this</li>\n  <li>2.\
      \ And don't do that</li>\n</ul>"
  - id: Content_25
    name: SECTION 5.5
    sectionNumber: '5.5'
    sectionTitle: Lifestyle Considerations
    text: ''
  - id: Content_26
    name: SECTION 5.5.1
    sectionNumber: 5.5.1
    sectionTitle: Meals and Dietary Restrictions
    text: ''
  - id: Content_27
    name: SECTION 5.5.2
    sectionNumber: 5.5.2
    sectionTitle: Caffeine, Alcohol, Tobacco, and Other Habits
    text: ''
  - id: Content_28
    name: SECTION 5.5.3
    sectionNumber: 5.5.3
    sectionTitle: Physical Activity
    text: ''
  - id: Content_29
    name: SECTION 5.5.4
    sectionNumber: 5.5.4
    sectionTitle: Other Activity
    text: ''
  - id: Content_30
    name: SECTION 5.6
    sectionNumber: '5.6'
    sectionTitle: Screen Failures
    text: ''
  - id: Content_31
    name: SECTION 6
    sectionNumber: '6'
    sectionTitle: TRIAL INTERVENTION AND CONCOMITANT THERAPY
    text: ''
  - id: Content_32
    name: SECTION 6.1
    sectionNumber: '6.1'
    sectionTitle: Description of Trial Intervention
    text: ''
  - id: Content_33
    name: SECTION 6.2
    sectionNumber: '6.2'
    sectionTitle: Rationale for Trial Intervention
    text: ''
  - id: Content_34
    name: SECTION 6.3
    sectionNumber: '6.3'
    sectionTitle: Dosing and Administration
    text: ''
  - id: Content_35
    name: SECTION 6.3.1
    sectionNumber: 6.3.1
    sectionTitle: Trial Intervention Dose Modification
    text: ''
  - id: Content_36
    name: SECTION 6.4
    sectionNumber: '6.4'
    sectionTitle: Treatment of Overdose
    text: ''
  - id: Content_37
    name: SECTION 6.5
    sectionNumber: '6.5'
    sectionTitle: Preparation, Handling, Storage and Accountability
    text: ''
  - id: Content_38
    name: SECTION 6.5.1
    sectionNumber: 6.5.1
    sectionTitle: Preparation of Trial Intervention
    text: ''
  - id: Content_39
    name: SECTION 6.5.2
    sectionNumber: 6.5.2
    sectionTitle: Handling and Storage of Trial Intervention
    text: ''
  - id: Content_40
    name: SECTION 6.5.3
    sectionNumber: 6.5.3
    sectionTitle: Accountability of Trial Intervention
    text: ''
  - id: Content_41
    name: SECTION 6.6
    sectionNumber: '6.6'
    sectionTitle: Participant Assignment, Randomisation and Blinding
    text: ''
  - id: Content_42
    name: SECTION 6.6.1
    sectionNumber: 6.6.1
    sectionTitle: Participant Assignment
    text: ''
  - id: Content_43
    name: SECTION 6.6.2
    sectionNumber: 6.6.2
    sectionTitle: Randomisation
    text: ''
  - id: Content_44
    name: SECTION 6.6.3
    sectionNumber: 6.6.3
    sectionTitle: Blinding and Unblinding
    text: <p>Blinding and unblinding text here please</p>
  - id: Content_45
    name: SECTION 6.7
    sectionNumber: '6.7'
    sectionTitle: Trial Intervention Compliance
    text: ''
  - id: Content_46
    name: SECTION 6.8
    sectionNumber: '6.8'
    sectionTitle: Concomitant Therapy
    text: ''
  - id: Content_47
    name: SECTION 6.8.1
    sectionNumber: 6.8.1
    sectionTitle: Prohibited Concomitant Therapy
    text: ''
  - id: Content_48
    name: SECTION 6.8.2
    sectionNumber: 6.8.2
    sectionTitle: Permitted Concomitant Therapy
    text: ''
  - id: Content_49
    name: SECTION 6.8.3
    sectionNumber: 6.8.3
    sectionTitle: Rescue Therapy
    text: ''
  - id: Content_50
    name: SECTION 6.8.4
    sectionNumber: 6.8.4
    sectionTitle: Other Therapy
    text: ''
  - id: Content_51
    name: SECTION 7
    sectionNumber: '7'
    sectionTitle: DISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL
      FROM TRIAL
    text: ''
  - id: Content_52
    name: SECTION 7.1
    sectionNumber: '7.1'
    sectionTitle: Discontinuation of Trial Intervention
    text: ''
  - id: Content_53
    name: SECTION 7.1.1
    sectionNumber: 7.1.1
    sectionTitle: Criteria for Permanent Discontinuation of Trial Intervention
    text: ''
  - id: Content_54
    name: SECTION 7.1.2
    sectionNumber: 7.1.2
    sectionTitle: Temporary Discontinuation or Interruption of Trial Intervention
    text: ''
  - id: Content_55
    name: SECTION 7.1.3
    sectionNumber: 7.1.3
    sectionTitle: Rechallenge
    text: ''
  - id: Content_56
    name: SECTION 7.2
    sectionNumber: '7.2'
    sectionTitle: Participant Withdrawal from the Trial
    text: ''
  - id: Content_57
    name: SECTION 7.3
    sectionNumber: '7.3'
    sectionTitle: Lost to Follow-Up
    text: ''
  - id: Content_58
    name: SECTION 7.4
    sectionNumber: '7.4'
    sectionTitle: Trial Stopping Rules
    text: ''
  - id: Content_59
    name: SECTION 8
    sectionNumber: '8'
    sectionTitle: TRIAL ASSESSMENTS AND PROCEDURES
    text: ''
  - id: Content_60
    name: SECTION 8.1
    sectionNumber: '8.1'
    sectionTitle: Screening/Baseline Assessments and Procedures
    text: ''
  - id: Content_61
    name: SECTION 8.2
    sectionNumber: '8.2'
    sectionTitle: Efficacy Assessments and Procedures
    text: ''
  - id: Content_62
    name: SECTION 8.3
    sectionNumber: '8.3'
    sectionTitle: Safety Assessments and Procedures
    text: ''
  - id: Content_63
    name: SECTION 8.3.1
    sectionNumber: 8.3.1
    sectionTitle: Physical Examination
    text: ''
  - id: Content_64
    name: SECTION 8.3.2
    sectionNumber: 8.3.2
    sectionTitle: Vital Signs
    text: ''
  - id: Content_65
    name: SECTION 8.3.3
    sectionNumber: 8.3.3
    sectionTitle: Electrocardiograms
    text: ''
  - id: Content_66
    name: SECTION 8.3.4
    sectionNumber: 8.3.4
    sectionTitle: Clinical Laboratory Assessments
    text: ''
  - id: Content_67
    name: SECTION 8.3.5
    sectionNumber: 8.3.5
    sectionTitle: Suicidal Ideation and Behaviour Risk Monitoring
    text: ''
  - id: Content_68
    name: SECTION 8.4
    sectionNumber: '8.4'
    sectionTitle: Adverse Events and Serious Adverse Events
    text: ''
  - id: Content_69
    name: SECTION 8.4.1
    sectionNumber: 8.4.1
    sectionTitle: Definitions of AE and SAE
    text: ''
  - id: Content_70
    name: SECTION 8.4.2
    sectionNumber: 8.4.2
    sectionTitle: Time Period and Frequency for Collecting AE and SAE Information
    text: ''
  - id: Content_71
    name: SECTION 8.4.3
    sectionNumber: 8.4.3
    sectionTitle: Identifying AEs and SAEs
    text: ''
  - id: Content_72
    name: SECTION 8.4.4
    sectionNumber: 8.4.4
    sectionTitle: Recording of AEs and SAEs
    text: ''
  - id: Content_73
    name: SECTION 8.4.5
    sectionNumber: 8.4.5
    sectionTitle: Follow-up of AEs and SAEs
    text: ''
  - id: Content_74
    name: SECTION 8.4.6
    sectionNumber: 8.4.6
    sectionTitle: Reporting of SAEs
    text: ''
  - id: Content_75
    name: SECTION 8.4.7
    sectionNumber: 8.4.7
    sectionTitle: Regulatory Reporting Requirements for SAEs
    text: ''
  - id: Content_76
    name: SECTION 8.4.8
    sectionNumber: 8.4.8
    sectionTitle: Serious and Unexpected Adverse Reaction Reporting
    text: ''
  - id: Content_77
    name: SECTION 8.4.9
    sectionNumber: 8.4.9
    sectionTitle: Adverse Events of Special Interest
    text: ''
  - id: Content_78
    name: SECTION 8.4.10
    sectionNumber: 8.4.10
    sectionTitle: Disease-related Events or Outcomes Not Qualifying as AEs or SAEs
    text: ''
  - id: Content_79
    name: SECTION 8.5
    sectionNumber: '8.5'
    sectionTitle: Pregnancy and Postpartum Information
    text: ''
  - id: Content_80
    name: SECTION 8.5.1
    sectionNumber: 8.5.1
    sectionTitle: Participants Who Become Pregnant During the Trial
    text: ''
  - id: Content_81
    name: SECTION 8.5.2
    sectionNumber: 8.5.2
    sectionTitle: Participants Whose Partners Become Pregnant
    text: ''
  - id: Content_82
    name: SECTION 8.6
    sectionNumber: '8.6'
    sectionTitle: Medical Device Product Complaints for Drug/Device Combination Products
    text: ''
  - id: Content_83
    name: SECTION 8.6.1
    sectionNumber: 8.6.1
    sectionTitle: Definition of Medical Device Product Complaints
    text: ''
  - id: Content_84
    name: SECTION 8.6.2
    sectionNumber: 8.6.2
    sectionTitle: Recording of Medical Device Product Complaints
    text: ''
  - id: Content_85
    name: SECTION 8.6.3
    sectionNumber: 8.6.3
    sectionTitle: Time Period and Frequency for Collecting Medical Device Product
      Complaints .
    text: ''
  - id: Content_86
    name: SECTION 8.6.4
    sectionNumber: 8.6.4
    sectionTitle: Follow-Up of Medical Device Product Complaints
    text: ''
  - id: Content_87
    name: SECTION 8.6.5
    sectionNumber: 8.6.5
    sectionTitle: Regulatory Reporting Requirements for Medical Device Product Complaints
    text: ''
  - id: Content_88
    name: SECTION 8.7
    sectionNumber: '8.7'
    sectionTitle: Pharmacokinetics
    text: ''
  - id: Content_89
    name: SECTION 8.8
    sectionNumber: '8.8'
    sectionTitle: Genetics
    text: ''
  - id: Content_90
    name: SECTION 8.9
    sectionNumber: '8.9'
    sectionTitle: Biomarkers
    text: ''
  - id: Content_91
    name: SECTION 8.1
    sectionNumber: '8.1'
    sectionTitle: Immunogenicity Assessments
    text: ''
  - id: Content_92
    name: SECTION 8.1.1
    sectionNumber: 8.1.1
    sectionTitle: Medical Resource Utilisation and Health Economics
    text: ''
  - id: Content_93
    name: SECTION 9
    sectionNumber: '9'
    sectionTitle: STATISTICAL CONSIDERATIONS
    text: ''
  - id: Content_94
    name: SECTION 9.1
    sectionNumber: '9.1'
    sectionTitle: Analysis Sets
    text: ''
  - id: Content_95
    name: SECTION 9.2
    sectionNumber: '9.2'
    sectionTitle: Analyses Supporting Primary Objective(s)
    text: ''
  - id: Content_96
    name: SECTION 9.2.1
    sectionNumber: 9.2.1
    sectionTitle: Statistical Model, Hypothesis, and Method of Analysis
    text: ''
  - id: Content_97
    name: SECTION 9.2.2
    sectionNumber: 9.2.2
    sectionTitle: Handling of Intercurrent Events of Primary Estimand(s)
    text: ''
  - id: Content_98
    name: SECTION 9.2.3
    sectionNumber: 9.2.3
    sectionTitle: Handling of Missing Data
    text: ''
  - id: Content_99
    name: SECTION 9.2.4
    sectionNumber: 9.2.4
    sectionTitle: Sensitivity Analysis
    text: ''
  - id: Content_100
    name: SECTION 9.2.5
    sectionNumber: 9.2.5
    sectionTitle: Supplementary Analysis
    text: ''
  - id: Content_101
    name: SECTION 9.3
    sectionNumber: '9.3'
    sectionTitle: Analysis Supporting Secondary Objective(s)
    text: ''
  - id: Content_102
    name: SECTION 9.4
    sectionNumber: '9.4'
    sectionTitle: Analysis of Exploratory Objective(s)
    text: ''
  - id: Content_103
    name: SECTION 9.5
    sectionNumber: '9.5'
    sectionTitle: Safety Analyses
    text: ''
  - id: Content_104
    name: SECTION 9.6
    sectionNumber: '9.6'
    sectionTitle: Other Analyses
    text: ''
  - id: Content_105
    name: SECTION 9.7
    sectionNumber: '9.7'
    sectionTitle: Interim Analyses
    text: ''
  - id: Content_106
    name: SECTION 9.8
    sectionNumber: '9.8'
    sectionTitle: Sample Size Determination
    text: ''
  - id: Content_107
    name: SECTION 9.9
    sectionNumber: '9.9'
    sectionTitle: Protocol Deviations
    text: ''
  - id: Content_108
    name: SECTION 10
    sectionNumber: '10'
    sectionTitle: 'GENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT'
    text: ''
  - id: Content_109
    name: SECTION 10.1
    sectionNumber: '10.1'
    sectionTitle: Regulatory and Ethical Considerations
    text: ''
  - id: Content_110
    name: SECTION 10.2
    sectionNumber: '10.2'
    sectionTitle: Committees
    text: ''
  - id: Content_111
    name: SECTION 10.3
    sectionNumber: '10.3'
    sectionTitle: Informed Consent Process
    text: ''
  - id: Content_112
    name: SECTION 10.4
    sectionNumber: '10.4'
    sectionTitle: Data Protection
    text: ''
  - id: Content_113
    name: SECTION 10.5
    sectionNumber: '10.5'
    sectionTitle: Early Site Closure or Trial Termination
    text: ''
  - id: Content_114
    name: SECTION 11
    sectionNumber: '11'
    sectionTitle: 'GENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE'
    text: ''
  - id: Content_115
    name: SECTION 11.1
    sectionNumber: '11.1'
    sectionTitle: Quality Tolerance Limits
    text: ''
  - id: Content_116
    name: SECTION 11.2
    sectionNumber: '11.2'
    sectionTitle: Data Quality Assurance
    text: ''
  - id: Content_117
    name: SECTION 11.3
    sectionNumber: '11.3'
    sectionTitle: Source Data
    text: ''
  - id: Content_118
    name: SECTION 12
    sectionNumber: '12'
    sectionTitle: 'APPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS - DEFINITIONS,
      SEVERITY, AND CAUSALITY'
    text: ''
  - id: Content_119
    name: SECTION 12.1
    sectionNumber: '12.1'
    sectionTitle: Further Details and Clarifications on the AE Definition
    text: ''
  - id: Content_120
    name: SECTION 12.2
    sectionNumber: '12.2'
    sectionTitle: Further Details and Clarifications on the SAE Definition
    text: ''
  - id: Content_121
    name: SECTION 12.3
    sectionNumber: '12.3'
    sectionTitle: Severity
    text: ''
  - id: Content_122
    name: SECTION 12.4
    sectionNumber: '12.4'
    sectionTitle: Causality
    text: ''
  - id: Content_123
    name: SECTION 13
    sectionNumber: '13'
    sectionTitle: 'APPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS'
    text: ''
  - id: Content_124
    name: SECTION 13.1
    sectionNumber: '13.1'
    sectionTitle: Contraception and Pregnancy Testing
    text: ''
  - id: Content_125
    name: SECTION 13.1.1
    sectionNumber: 13.1.1
    sectionTitle: Definitions Related to Childbearing Potential
    text: ''
  - id: Content_126
    name: SECTION 13.1.2
    sectionNumber: 13.1.2
    sectionTitle: Contraception
    text: ''
  - id: Content_127
    name: SECTION 13.1.3
    sectionNumber: 13.1.3
    sectionTitle: Pregnancy Testing
    text: ''
  - id: Content_128
    name: SECTION 13.2
    sectionNumber: '13.2'
    sectionTitle: Clinical Laboratory Tests
    text: ''
  - id: Content_129
    name: SECTION 13.3
    sectionNumber: '13.3'
    sectionTitle: Country/Region-Specific Differences
    text: ''
  - id: Content_130
    name: SECTION 13.4
    sectionNumber: '13.4'
    sectionTitle: Prior Protocol Amendments
    text: ''
  - id: Content_131
    name: SECTION 14
    sectionNumber: '14'
    sectionTitle: 'APPENDIX: GLOSSARY OF TERMS'
    text: ''
  - id: Content_132
    name: SECTION 15
    sectionNumber: '15'
    sectionTitle: 'APPENDIX: REFERENCES'
    text: ''
  Encounter:
  - description: Screening encounter
    id: Encounter_1
    label: ''
    name: Screening
  - description: Baseline encounter
    id: Encounter_2
    label: ''
    name: Baseline
    transitionEndRule: null
    transitionStartRule: null
  - description: First dose
    id: Encounter_3
    label: ''
    name: 15 min
    transitionEndRule: null
  - description: 2 week visit
    id: Encounter_4
    label: ''
    name: Day 24
    transitionEndRule: null
    transitionStartRule: null
  - description: 5 week visit
    id: Encounter_5
    label: ''
    name: Day 35
    transitionEndRule: null
    transitionStartRule: null
  Endpoint:
  - description: Clinical status assessed using a 7-category ordinal scale at Day
      28
    id: Endpoint_1
    purpose: None provided
  - description: Time to clinical improvement (TTCI) defined as a National Early Warning
      Score 2 (NEWS2) of <=2 maintained for 24 hours
    id: Endpoint_2
    purpose: None provided
  - description: Time to improvement of at least 2 categories relative to baseline
      on a 7-category ordinal scale of clinical status
    id: Endpoint_3
    purpose: None provided
  - description: Incidence of mechanical ventilation
    id: Endpoint_4
    purpose: None provided
  - description: Ventilator-free days to Day 28
    id: Endpoint_5
    purpose: None provided
  - description: Incidence of intensive care unit (ICU) stay
    id: Endpoint_6
    purpose: None provided
  - description: Duration of ICU stay
    id: Endpoint_7
    purpose: None provided
  - description: Time to clinical failure, defined as the time to death, mechanical
      ventilation, ICU admission, or withdrawal (whichever occurs first). For patients
      entering the study already in ICU or on mechanical ventilation, clinical failure
      is defined as a one-category worsening on the ordinal scale, withdrawal or death.
    id: Endpoint_8
    purpose: None provided
  - description: Mortality rate at Days 7, 14, 21, 28, and 60
    id: Endpoint_9
    purpose: None provided
  - description: "Time to hospital discharge or \u201Cready for discharge\u201D (as\
      \ evidenced by normal body temperature and respiratory rate, and stable oxygen\
      \ saturation on ambient air or <= 2L supplemental oxygen)"
    id: Endpoint_10
    purpose: None provided
  - description: "Time to recovery, defined as discharged or \u201Cready for discharge\u201D\
      \ (as evidenced by normal body temperature and respiratory rate, and stable\
      \ oxygen saturation on ambient air or <= 2L supplemental oxygen); OR, in a non-ICU\
      \ hospital ward (or \u201Cready for hospital ward\u201D) not requiring supplemental\
      \ oxygen"
    id: Endpoint_11
    purpose: None provided
  - description: Duration of supplemental oxygen
    id: Endpoint_12
    purpose: None provided
  Estimand:
  - id: Estimand_1
    summaryMeasure: Survival of all patients
  - id: Estimand_2
    summaryMeasure: Something else
  Indication:
  - description: An indication
    id: Indication_1
    label: ''
    name: IND1
  - description: An indication
    id: Indication_2
    label: ''
    name: IND2
  IntercurrentEvent:
  - description: IC Event Description
    id: IntercurrentEvent_1
    intercurrentEventStrategy: Patients with out of range lab values before dosing
      will be excluded
    label: ''
    name: termination
  - description: IC Event Description
    id: IntercurrentEvent_2
    intercurrentEventStrategy: A second bad event
    label: ''
    name: termination
  - description: IC Event Description
    id: IntercurrentEvent_3
    intercurrentEventStrategy: A third bad thing
    label: ''
    name: termination
  - description: IC Event Description Number 2
    id: IntercurrentEvent_4
    intercurrentEventStrategy: Really really bad shit
    label: ''
    name: Bad stuff
  InvestigationalIntervention:
  - description: An intervention
    id: InvestigationalIntervention_1
  - description: An intervention
    id: InvestigationalIntervention_2
  Objective:
  - description: The primary efficacy objective for this study is to evaluate the
      efficacy of TCZ compared with placebo in combination with SOC for the treatment
      of severe COVID-19 pneumonia
    id: Objective_1
    label: ''
    name: OBJ1
  - description: The secondary efficacy objective for this study is to evaluate the
      efficacy of TCZ compared with placebo in combination with SOC for the treatment
      of severe COVID-19 pneumonia
    id: Objective_2
    label: ''
    name: OBJ2
  Organization:
  - id: Organization_1
    label: ''
    name: ClinicalTrials.gov
    organizationIdentifier: CT-GOV
    organizationIdentifierScheme: USGOV
  - id: Organization_2
    label: ''
    name: ACME Pharma
    organizationIdentifier: '123456789'
    organizationIdentifierScheme: DUNS
  ResponseCode:
  - id: ResponseCode_1
    responseCodeEnabled: true
  - id: ResponseCode_2
    responseCodeEnabled: true
  - id: ResponseCode_3
    responseCodeEnabled: true
  - id: ResponseCode_4
    responseCodeEnabled: true
  - id: ResponseCode_5
    responseCodeEnabled: true
  - id: ResponseCode_6
    responseCodeEnabled: true
  - id: ResponseCode_7
    responseCodeEnabled: true
  ScheduleTimeline:
  - description: This is the main timeline for the study design.
    entryCondition: Potential subject identified
    id: ScheduleTimeline_1
    label: Main Timeline
    mainTimeline: true
    name: Main Timeline
  ScheduleTimelineExit:
  - id: ScheduleTimelineExit_1
  ScheduledActivityInstance:
  - id: ScheduledActivityInstance_1
    instanceType: ACTIVITY
  - id: ScheduledActivityInstance_2
    instanceType: ACTIVITY
  - id: ScheduledActivityInstance_3
    instanceType: ACTIVITY
  - id: ScheduledActivityInstance_4
    instanceType: ACTIVITY
  - id: ScheduledActivityInstance_5
    instanceType: ACTIVITY
  Study:
  - id: Study
    studyAcronym: SIMPLE
    studyRationale: A simple test
    studyTitle: Simple Test 1
    studyVersion: '1'
  StudyArm:
  - description: Active Substance
    id: StudyArm_1
    label: ''
    name: Active
    studyArmDataOriginDescription: Data collected from subjects
  - description: Placebo
    id: StudyArm_2
    label: ''
    name: Placebo
    studyArmDataOriginDescription: Data collected from subjects
  StudyCell:
  - id: StudyCell_1
  - id: StudyCell_2
  - id: StudyCell_3
  - id: StudyCell_4
  - id: StudyCell_5
  - id: StudyCell_6
  - id: StudyCell_7
  - id: StudyCell_8
  StudyDesign:
  - bcCategories: []
    description: The main design for the study
    id: StudyDesign_1
    label: ''
    name: Study Design 1
    studyDesignRationale: Basic study
  StudyDesignPopulation:
  - description: Pop 1
    id: StudyDesignPopulation_1
    label: ''
    name: POP 1
    plannedMaximumAgeOfParticipants: 40 years
    plannedMinimumAgeOfParticipants: 18 years
    plannedNumberOfParticipants: 100
  - description: Pop 2
    id: StudyDesignPopulation_2
    label: ''
    name: POP 2
    plannedMaximumAgeOfParticipants: 60 years
    plannedMinimumAgeOfParticipants: 18 years
    plannedNumberOfParticipants: 20
  - description: Pop 3
    id: StudyDesignPopulation_3
    label: ''
    name: POP 3
    plannedMaximumAgeOfParticipants: 70 years
    plannedMinimumAgeOfParticipants: 18 years
    plannedNumberOfParticipants: 20
  StudyElement:
  - description: Screening Element
    id: StudyElement_1
    label: ''
    name: Screening
  - description: Baseline Element
    id: StudyElement_2
    label: ''
    name: Baseline
  - description: Treatment Element 1
    id: StudyElement_3
    label: ''
    name: Treatment 1
  - description: Treatment Element 2
    id: StudyElement_5
    label: ''
    name: Treatment 2
  - description: Follow Up Element
    id: StudyElement_4
    label: ''
    name: Follow Up
  StudyEpoch:
  - description: Screening Epoch
    id: StudyEpoch_1
    label: ''
    name: Screening
  - description: Baseline Epoch
    id: StudyEpoch_2
    label: ''
    name: Baseline
  - description: Treatment Epoch
    id: StudyEpoch_3
    label: ''
    name: Treatment
  - description: Follow-up Epoch
    id: StudyEpoch_4
    label: ''
    name: Follow-Up
  StudyIdentifier:
  - id: StudyIdentifier_1
    studyIdentifier: NCT12345678
  - id: StudyIdentifier_2
    studyIdentifier: AP1234
  StudyProtocolVersion:
  - briefTitle: Something Brief
    id: StudyProtocolVersion_1
    officialTitle: Something Very Official
    protocolAmendment: ''
    protocolEffectiveDate: '2010-01-01'
    protocolVersion: '1'
    publicTitle: Something Public
    scientificTitle: Somethign Clever
  - briefTitle: Something Brief
    id: StudyProtocolVersion_2
    officialTitle: Something Very Official
    protocolAmendment: A
    protocolEffectiveDate: '2011-01-01'
    protocolVersion: '1'
    publicTitle: Something Public
    scientificTitle: Somethign Clever But New
  Timing:
  - description: null
    id: Timing_1
    label: ''
    name: TIMING_3
    timingValue: PT0M
    timingWindow: null
    timingWindowLower: null
    timingWindowUpper: null
  - description: Pre Dose
    id: Timing_2
    label: ''
    name: TIMING_4
    timingValue: PT0M
    timingWindow: 0..4 Hours
    timingWindowLower: PT0H
    timingWindowUpper: PT4H
  - description: null
    id: Timing_3
    label: ''
    name: TIMING_5
    timingValue: PT0M
    timingWindow: 0..1 Hours
    timingWindowLower: PT0H
    timingWindowUpper: PT1H
  - description: +24 Hours
    id: Timing_4
    label: ''
    name: TIMING_6
    timingValue: PT24H
    timingWindow: null
    timingWindowLower: null
    timingWindowUpper: null
  - description: +7 Days
    id: Timing_5
    label: ''
    name: TIMING_7
    timingValue: P7D
    timingWindow: -3..3 Days
    timingWindowLower: P3D
    timingWindowUpper: P3D
  TransitionRule:
  - description: Subject identified
    id: TransitionRule_1
  - description: IEs passed
    id: TransitionRule_2
  - description: Radomized
    id: TransitionRule_3
  - description: Study Start
    id: TransitionRule_4
  - description: Screened
    id: TransitionRule_5
  - description: Screened
    id: TransitionRule_6
  - description: Radomized
    id: TransitionRule_7
  - description: Radomized
    id: TransitionRule_8
  - description: Completed treatment 1
    id: TransitionRule_9
  - description: Radomized
    id: TransitionRule_12
  - description: Completed treatment 2
    id: TransitionRule_13
  - description: Treated
    id: TransitionRule_10
  - description: Leave Study
    id: TransitionRule_11
